Skip to main content

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Fireside Chat: Wednesday, February 14, 2024 at 10:00 am ET
Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.32
-2.14 (-0.80%)
AAPL  308.82
+3.83 (1.26%)
AMD  467.51
+17.92 (3.99%)
BAC  51.80
+0.31 (0.60%)
GOOG  379.38
-4.09 (-1.07%)
META  610.26
+2.88 (0.47%)
MSFT  418.57
-0.52 (-0.12%)
NVDA  215.33
-4.18 (-1.90%)
ORCL  192.08
+2.31 (1.22%)
TSLA  426.01
+8.16 (1.95%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.